UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 26

Sortiert nach

Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)

British journal of cancer, 2020-07, Vol.123 (1), p.26-32

2020

Link zum Volltext

Verfügbarkeit prüfen

Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer

Journal for immunotherapy of cancer, 2021-03, Vol.9 (3), p.e001865

2021

Link zum Volltext

Verfügbarkeit prüfen

Palliative Short-Course Radiation Therapy in Rectal Cancer: A Phase 2 Study

International journal of radiation oncology, biology, physics, 2016-07, Vol.95 (4), p.1184-1190

2016

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2016-11, Vol.375 (19), p.1823-1833

2016

Link zum Volltext

Verfügbarkeit prüfen

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2019-12, Vol.20 (12), p.1655-1669

2019

Link zum Volltext

Verfügbarkeit prüfen

Standard Versus Intensified Chemotherapy With Granulocyte Colony-Stimulating Factor Support in Small-Cell Lung Cancer: A Prospective European Organization for Research and Treatment of Cancer–Lung Cancer Group Phase III Trial—08923

Journal of clinical oncology, 2002-10, Vol.20 (19), p.3947-3955

2002

Link zum Volltext

Verfügbarkeit prüfen

European Organization for Research and Treatment of Cancer (EORTC) 08957 Phase II Study of Topotecan in Combination with Cisplatin as Second-Line Treatment of Refractory and Sensitive Small Cell Lung Cancer

Clinical cancer research, 2003-01, Vol.9 (1), p.143-150

2003

Link zum Volltext

Verfügbarkeit prüfen

Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial

The oncologist (Dayton, Ohio), 2024-05, Vol.29 (5), p.e690-e698

2024

Link zum Volltext

Verfügbarkeit prüfen

PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: the role of salvage chemo-immunotherapy combination

Immunotherapy, 2021-04, Vol.13 (5), p.363-369

2021

Link zum Volltext

Verfügbarkeit prüfen

BOLERO-3 results: pharmacological activity or pharmacokinetic effect?

The lancet oncology, 2014-07, Vol.15 (8), p.e304-e304

2014

Link zum Volltext

Verfügbarkeit prüfen

CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients

Tumor biology, 2015-08, Vol.36 (8), p.5943-5951

2015

Link zum Volltext

Verfügbarkeit prüfen

Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab

Immunotherapy, 2018-06, Vol.10 (8), p.681-694

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH

Tumori, 2015-03, Vol.101 (2), p.e51-e53

2015

Link zum Volltext

Verfügbarkeit prüfen

Concurrent Chemoradiation with Concomitant Boost in Locally Advanced Rectal Cancer: A Phase II Study

Anticancer research, 2016-08, Vol.36 (8), p.4081

2016

Link zum Volltext

Verfügbarkeit prüfen

Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study

Journal of cancer research and clinical oncology, 2014-10, Vol.140 (10), p.1783-1793

2014

Link zum Volltext

Verfügbarkeit prüfen

Management of Italian Patients With Advanced Non–Small-Cell Lung Cancer After Second-Line Treatment: Results of the Longitudinal Phase of the LIFE Observational Study

Clinical lung cancer, 2014-09, Vol.15 (5), p.338-345.e1

2014

Link zum Volltext

Verfügbarkeit prüfen

Colony-Stimulating Factors for Febrile Neutropenia

The New England journal of medicine, 2013, Vol.369 (3), p.284-286

2013

Link zum Volltext

Verfügbarkeit prüfen

Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)

Lung cancer (Amsterdam, Netherlands), 2003-08, Vol.41 (2), p.227-231

2003

Link zum Volltext

Verfügbarkeit prüfen

Strong Notch activation hinders bevacizumab efficacy in advanced colorectal cancer

Future oncology (London, England), 2015-01, Vol.11 (23), p.3167-3174

2015

Link zum Volltext

Verfügbarkeit prüfen

Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: Results from the Italian observational “SUN” (Survey on the lUng cancer maNagement) study

Lung cancer (Amsterdam, Netherlands), 2011-12, Vol.74 (3), p.462-468

2011

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956)

Lung cancer (Amsterdam, Netherlands), 2005-10, Vol.50 (1), p.91-96

2005

Link zum Volltext

Verfügbarkeit prüfen

Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

Journal of clinical oncology, 1996-03, Vol.14 (3), p.814-820

1996

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of taxol combined with ifosfamide and carboplatin in the treatment of stage IIIb-IV non-small-cell lung cancer

American journal of clinical oncology, 2003-02, Vol.26 (1), p.84-88

2003

Link zum Volltext

Verfügbarkeit prüfen

Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy : a dose-finding study in patients with advanced breast cancer

Cancer chemotherapy and pharmacology, 1996, Vol.38 (6), p.487-494

1996

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 26

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SeriePlos One

ThemaChemotherapy

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(26)

Sprache

Englisch
(26)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Humans
(26)
Life Sciences & Biomedicine
(24)
Middle Aged
(24)
Science & Technology
(24)
Aged
(23)
Male
(21)
Oncology
(21)
Adult
(19)
Lung Neoplasms - Drug Therapy
(15)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(13)
Lung Neoplasms - Pathology
(13)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(12)
Aged, 80 And Over
(10)
Treatment Outcome
(10)
Biological And Medical Sciences
(9)
Carcinoma, Non-Small-Cell Lung - Pathology
(9)
Medical Sciences
(9)
Antineoplastic Agents
(7)

13 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)

Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer

Palliative Short-Course Radiation Therapy in Rectal Cancer: A Phase 2 Study

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Standard Versus Intensified Chemotherapy With Granulocyte Colony-Stimulating Factor Support in Small-Cell Lung Cancer: A Prospective European Organization for Research and Treatment of Cancer–Lung Cancer Group Phase III Trial—08923

European Organization for Research and Treatment of Cancer (EORTC) 08957 Phase II Study of Topotecan in Combination with Cisplatin as Second-Line Treatment of Refractory and Sensitive Small Cell Lung Cancer

Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial

PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: the role of salvage chemo-immunotherapy combination

BOLERO-3 results: pharmacological activity or pharmacokinetic effect?

CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients

Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab

Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH

Concurrent Chemoradiation with Concomitant Boost in Locally Advanced Rectal Cancer: A Phase II Study

Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC

Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study

Management of Italian Patients With Advanced Non–Small-Cell Lung Cancer After Second-Line Treatment: Results of the Longitudinal Phase of the LIFE Observational Study

Colony-Stimulating Factors for Febrile Neutropenia

Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)

Strong Notch activation hinders bevacizumab efficacy in advanced colorectal cancer

Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: Results from the Italian observational “SUN” (Survey on the lUng cancer maNagement) study

A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956)

Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

Phase II study of taxol combined with ifosfamide and carboplatin in the treatment of stage IIIb-IV non-small-cell lung cancer

Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy : a dose-finding study in patients with advanced breast cancer

Aktive Filter

Suchergebnisse filtern